<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493242</url>
  </required_header>
  <id_info>
    <org_study_id>DB-001</org_study_id>
    <nct_id>NCT04493242</nct_id>
  </id_info>
  <brief_title>Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS</brief_title>
  <acronym>EXIT-COVID19</acronym>
  <official_title>Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direct Biologics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direct Biologics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of intravenous administration of bone marrow derived&#xD;
      extracellular vesicles, ExoFlo, versus placebo as treatment for moderate-to-severe Acute&#xD;
      Respiratory Distress Syndrome (ARDS) in patients with severe COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EXIT COVID-19 is a FDA-approved, phase II double-blinded, placebo-controlled randomized&#xD;
      controlled trial that enrolled 120 patients admitted with COVID-19 associated&#xD;
      moderate-to-severe ARDS across up to 15 hospital sites in the United States.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Actual">May 22, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-center, double-blinded, placebo-controlled, randomized controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>7 Day Improvement in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio</measure>
    <time_frame>61 days</time_frame>
    <description>Efficacy Endpoint; PaO2/FiO2 ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery</measure>
    <time_frame>61 days</time_frame>
    <description>The number of days from the first study treatment until return of oxygenation saturation (SpO2) ≥ 93% on room air (or PaO2/FiO2 ≥ 300 mmHg). If patient has chronic lung disease, recovery is defined as pre-COVID-19 SpO2 and O2 support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>61 days</time_frame>
    <description>Safety Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>61 days</time_frame>
    <description>Efficacy Endpoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribonucleic Acid (RNA) Level</measure>
    <time_frame>Days = 1, 4, 7, 10, 15, 29 *Labs are not drawn after hospitalization.</time_frame>
    <description>Viremia</description>
  </other_outcome>
  <other_outcome>
    <measure>CRP, D-dimer, Ferritin, IL-6, TNF-α</measure>
    <time_frame>Days = 1, 4, 7, 10, 15, 29 *Labs are not drawn after hospitalization</time_frame>
    <description>Acute Phase Reactants</description>
  </other_outcome>
  <other_outcome>
    <measure>Absolute Neutrophil Count (ANC), CD3+, CD4+, and CD8+ T Cells, NK Cells</measure>
    <time_frame>Days = 1, 4, 7, 10, 15, 29 *Labs are not drawn after hospitalization.</time_frame>
    <description>Immune Cell Counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA)</measure>
    <time_frame>Days = 1, 15, 29 *Labs are only drawn if patient is still hospitalized.</time_frame>
    <description>Mortality Prediction Score Ranging from 0 to 24 with Higher SOFA Score Correlating with Higher Mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D-5L Description Part Only, Which Includes 5 Dimensions of Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety Depression)</measure>
    <time_frame>Days = 15, 29, and 61 *Only Assessed for Outpatients</time_frame>
    <description>Standardized Quality of Life Metric Where Each Dimension Is Assessed via 5 Levels; 5 Levels for Each Digit is Combined into a 5 Digit Descriptor.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Covid19</condition>
  <condition>ARDS</condition>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 100 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DB-001</intervention_name>
    <description>Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles</description>
    <arm_group_label>Experimental Dose 1</arm_group_label>
    <arm_group_label>Experimental Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous normal saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form (either by the individual or by&#xD;
             the individual's healthcare proxy).&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 18-85.&#xD;
&#xD;
          4. COVID-19 positive as defined by positive RT-PCR SARS-CoV-2.&#xD;
&#xD;
          5. Moderate to severe ARDS as defined by modified Berlin definition*, which includes&#xD;
             timing within 1 week of known clinical insult or new or worsening respiratory&#xD;
             symptoms; bilateral opacities not fully explained by effusions, or lung collapse;&#xD;
             respiratory failure not fully explained by cardiac failure or fluid overload;&#xD;
             PaO2/FiO2 ≤ 200 mm Hg.&#xD;
&#xD;
          6. Hypoxia requiring noninvasive oxygen support such as Nasal Cannula (NC), Nonrebreather&#xD;
             (NRB), Bilevel Positive Airway Pressure (BIPAP), Continuous Positive Airway Pressure&#xD;
             (CPAP), high flow nasal cannula oxygen (HFNC O2) or mechanical ventilation (MV)&#xD;
             despite initiating standard of care.&#xD;
&#xD;
          7. If the candidate is either a male or female of reproductive potential, he or she must&#xD;
             agree to use of double barrier method of highly effective birth control contraception&#xD;
             such as condoms with oral contraceptive pill or choose to remain abstinent if already&#xD;
             practicing abstinence during the screening period. The required duration of usage of&#xD;
             double barrier method OR maintenance of abstinence must include the time from the&#xD;
             beginning of the screening period until 90 days following the last dose of the study&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Vulnerable populations such as pregnant patients, children, individuals with severe&#xD;
             physical or mental disabilities who cannot provide meaningful consent.&#xD;
&#xD;
          2. Active malignancy requiring treatment within the last five years.&#xD;
&#xD;
          3. Major physical trauma in the last 5 days, including motor vehicle accidents, assaults,&#xD;
             mechanical falls with sequalae of significant bleeding or craniofacial bruising, and&#xD;
             surgeries.&#xD;
&#xD;
          4. Active tuberculosis or cystic fibrosis.&#xD;
&#xD;
          5. Severe chronic respiratory disease including chronic obstructive pulmonary disease or&#xD;
             pulmonary fibrosis requiring home oxygen &gt; 5L/min.&#xD;
&#xD;
          6. Use of extracorporeal membrane oxygenation (ECMO) during the current hospitalization.&#xD;
&#xD;
          7. Pre-existing pulmonary hypertension.&#xD;
&#xD;
          8. Severe pre-existing hepatic impairment (presence of cirrhosis, liver function tests&#xD;
             (LFTs) ≥ 6x baseline, INR ≥ 2.0).&#xD;
&#xD;
          9. Pre-existing Chronic Kidney Disease (CKD) stage IIIb or End Stage Renal Disease (ESRD)&#xD;
             prior to onset of COVID-19 (stage I, II, and IIIa are acceptable)&#xD;
&#xD;
         10. Irreversible coagulopathy (e.g., frequently occluded vascular access despite&#xD;
             anticoagulation, precipitous platelet drops concurrent with end-organ damage&#xD;
             suggesting consumptive process) or irreversible bleeding disorder (e.g., frequent&#xD;
             bleeding from vascular access, endotracheal tubes, and foley).&#xD;
&#xD;
         11. Pneumonia clearly attributable to a non-COVID-19 related process, including aspiration&#xD;
             pneumonia or pneumonia that is exclusively bacterial, or originating from a diagnosed&#xD;
             alternative virus (e.g., influenza).&#xD;
&#xD;
         12. Patients who are not full code.&#xD;
&#xD;
         13. Endotracheal intubation duration ≤ 24 hours.&#xD;
&#xD;
         14. Moribund-expected survival &lt; 24 hours.&#xD;
&#xD;
         15. Severe metabolic disturbances on presentation (e.g., ketoacidosis, pH &lt; 7.3)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikram Sengupta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Heritage</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donald Guthrie Foundation/ Robert Packer Hospital</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Health</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRX Research</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://directbiologics.com/</url>
    <description>Direct Biologics, LLC</description>
  </link>
  <reference>
    <citation>Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020 Jun 15;29(12):747-754. doi: 10.1089/scd.2020.0080. Epub 2020 May 12.</citation>
    <PMID>32380908</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Direct Biologics, LLC</investigator_affiliation>
    <investigator_full_name>Vikram Sengupta</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>ARDS</keyword>
  <keyword>extracellular vesicles</keyword>
  <keyword>exosome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

